Repositioning Candidate Details
| Candidate ID: | R0223 |
| Source ID: | DB00630 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Alendronic acid |
| Synonyms: | (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid); (4-amino-1-hydroxybutylidene)bisphosphonic acid; 4-amino-1-hydroxybutane-1,1-diphosphonic acid; ABDP; Alendronate; Alendronic acid |
| Molecular Formula: | C4H13NO7P2 |
| SMILES: | NCCCC(O)(P(O)(O)=O)P(O)(O)=O |
| Structure: |
|
| DrugBank Description: | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone. |
| CAS Number: | 66376-36-1 |
| Molecular Weight: | 249.096 |
| DrugBank Indication: | Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min. |
| DrugBank Pharmacology: | Alendronic acid tablets have a very low oral bioavialability. After administration it distributes into soft tissue and bone or is excreted in the urine. Alendronic acid does not undergo metabolism. |
| DrugBank MoA: | Alendronic acid binds to bone hydroxyapatite. Bone resorption causes local acidification, releasing alendronic acid which is that taken into osteoclasts by fluid-phase endocytosis. Endocytic vesicles are acidified, releasing alendronic acid to the cytosol of osteoclasts where they induce apoptosis. Inhibition of osteoclasts results in decreased bone resorption which is shown through decreased urinary calcium, deoxypyridinoline and cross-linked N-telopeptidases of type I collagen. |
| Targets: | Farnesyl pyrophosphate synthase inhibitor; Hydroxylapatite antagonist; Tyrosine-protein phosphatase non-receptor type 4 inhibitor; Receptor-type tyrosine-protein phosphatase S inhibitor; Receptor-type tyrosine-protein phosphatase epsilon inhibitor; V-type proton ATPase catalytic subunit A inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |